Referencias bibliográficas
- CobbMeritxell Bellet, Faten Ahmad, Rafael Villanueva et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med Oncol 2019, Vol. 11: 1– 43
- Manqi Hua,Fei Xiong,Shan Chong et al. Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation. Cancer Treatment Reviews 130 (2024) 102827
- T. Ramón y Cajal Æ A. Alte´s Æ L. Pare et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat. 2010 Jan;119(1):33-8
- Kazuma Kiyotani, Taisei Mushiroda, Chiyo K. Imamura. Et al. Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients. J Clin Oncol 2010. 28:1287-1293.
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 May;103(5):770-777.
- icholson WK, Silverstein M,Wong JB, et al; US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22): 1918-1930. doi:10.1001/jama.2024.5534
